LeMaitre Vascular (NASDAQ:LMAT) Updates FY24 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $1.73-1.84 for the period, compared to the consensus EPS estimate of $1.65. The company issued revenue guidance of $212.7-217.3 million, compared to the consensus revenue estimate of $211.69 million. LeMaitre Vascular also updated its Q2 guidance to $0.45-0.50 EPS.

LeMaitre Vascular Trading Down 0.0 %

LMAT traded down $0.01 during trading on Thursday, hitting $66.77. The stock had a trading volume of 176,662 shares, compared to its average volume of 114,195. The firm has a market cap of $1.50 billion, a PE ratio of 49.83, a P/E/G ratio of 2.79 and a beta of 0.88. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64. The company has a 50 day simple moving average of $65.69 and a 200-day simple moving average of $58.53.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The company had revenue of $48.90 million for the quarter, compared to analyst estimates of $49.01 million. During the same period last year, the business posted $0.25 EPS. The business's quarterly revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts anticipate that LeMaitre Vascular will post 1.66 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, March 14th were given a $0.16 dividend. The ex-dividend date was Wednesday, March 13th. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a yield of 0.96%. LeMaitre Vascular's payout ratio is 47.76%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Tuesday, April 16th. Barrington Research boosted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an outperform rating in a research note on Wednesday, February 28th. KeyCorp began coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a sector weight rating for the company. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and boosted their price target for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $69.33.

Insider Transactions at LeMaitre Vascular

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of LeMaitre Vascular stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the completion of the sale, the chief financial officer now owns 6,452 shares of the company's stock, valued at approximately $450,091.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,036 shares of company stock worth $7,873,749. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.